Therapeutic options for intermediate-advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 17, Issue 13, 2011, Pages 1685-1689

  Zhang, Zong Ming ^a   Guo, Jin Xing ^a   Zhang, Zi Chao ^a   Jiang, Nan ^a   Zhang, Zhen Ya ^a   Pan, Li Jie ^a  

^a Tsinghua University   (China)

Author keywords

Hepatocellular carcinoma; Intermediate advanced; Interventional treatment; Molecularly targeted therapy; Surgical procedure

Indexed keywords

ACETIC ACID; ALCOHOL; ANTINEOPLASTIC AGENT; ARGON; BEVACIZUMAB PLUS ERLOTINIB; BRIVANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; HELIUM; LAPATINIB; LIQUID NITROGEN; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CRYOSURGERY; CRYOTHERAPY; HEPATIC ARTERY; HUMAN; INOPERABLE CANCER; LASER SURGERY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; PORTAL VEIN; QUALITY OF LIFE; RADICAL RESECTION; RADIOFREQUENCY ABLATION; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR ABLATION; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

EID: 79955971800     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i13.1685     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. He AR, Soe K, El Zouhairi M. Current problems with systemic treatment of advanced hepatocellular cancer. Curr Probl Cancer 2010; 34: 131-149
3. Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010; 25: 1023-1025
4. Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. World J Hepatol 2010; 2: 103-113
5. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216
6. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008; 14: 6437-6441
7. Wu MC. Status and prospect of comprehensive treatment of liver cancer. Zhonghua Gandan Waike Zazhi 2006; 12: 1-4
8. Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 2004; 11: 298-303
9. Wakabayashi H, Ushiyama T, Ishimura K, Izuishi K, Karasawa Y, Masaki T, Watanabe S, Kuriyama S, Maeta H. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol 2003; 82: 98-103
10. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 71: 62-65
11. Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol 2011; 137: 139-149
12. Morris-Stiff G, Gomez D, de Liguori Carino N, Prasad KR. Surgical management of hepatocellular carcinoma: is the jury still out? Surg Oncol 2009; 18: 298-321
13. Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606-2612
14. Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg 2007; 31: 2370-2377
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
16. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151
17. Chen XP, Zhang ZW. Attach great importance to standardization of surgical treatment of hepatoma. Zhonghua Xiaohua Waike Zazhi 2007; 6: 5-7
18. Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009; 13: 1313-1320
19. Capussotti L, Ferrero A, Viganò L, Polastri R, Tabone M. Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol 2009; 35: 11-15
20. Wang J. The standardized strategy for hepatocellular carcinoma. Shiyong Yixue Zazhi 2007; 23: 783-785
21. Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 2008; 134: 1831-1835
22. Gravante G, Sconocchia G, Ong SL, Dennison AR, Lloyd DM. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 2009; 29: 18-24
23. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010; 78 Suppl 1: 113-124
24. Cheung TT, Ng KK, Chok KS, Chan SC, Poon RT, Lo CM, Fan ST. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol 2010; 16: 3056-3062
25. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17
26. Hinshaw JL, Lee FT Jr. Cryoablation for liver cancer. Tech Vasc Interv Radiol 2007; 10: 47-57
27. Fan YF, Fang CH, Huang ZH, Xiang N, Yang J. [Intraoperative argon cryosurgery in surgical resection of advanced hepatic carcinoma: safety and efficacy]. Nanfang Yike Daxue Xuebao 2008; 28: 2035-2037
28. Li JC, Lu WQ, Liu HY, Cui SZ, Hu WM, Tang YQ. Hepatic artery and portal vein dual perfusion embolization and chemotherapy after radical resection of primary hepatic carcinoma for preventing tumor recurrence. Zhonghua Zhongliu Fangzhi Zazhi 2004; 11: 1074-1075
29. Shi LP, Zhang DS, Yu J, Bu XY, Chen ZY. Therapeutic effect of hepatectomy combined with hepatic arterial chemoembolization on patients with advanced liver carcinoma. Qilu Yixue Zazhi 2010; 25: 21-23
30. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247: 49-57
31. Haghighi KS, Glenn D, Gruenberger T, Morris DL. Extending the limits for curative liver resections by portal vein embolization. Int Surg 2009; 94: 43-47
32. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139: 766-774
33. Di Carlo I, Pulvirenti E, Toro A, Patanè D. Simultaneous transarterial and portal embolization for unresectable tumors of the liver. Hepatogastroenterology 2010; 57: 140-145
34. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391
35. Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K. Intra-arterial 5-fluorouracil/ interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol 2010; 25: 1117-1122
36. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44: 1477-1486
37. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003
38. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 466-486
39. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010; 12: 313-320
40. Ribero D, Curley SA, Imamura H, Madoff DC, Nagorney DM, Ng KK, Donadon M, Vilgrain V, Torzilli G, Roh M, Vauthey JN. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol 2008; 15: 986-992
41. Dhanasekaran R, Khanna V, Kooby DA, Spivey JR, Parekh S, Knechtle SJ, Carew JD, Kauh JS, Kim HS. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 1197-1204; quiz 1204
42. Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010; 25: 1299-1305
43. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480
44. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010; 17: 1247-1256
45. Tanaka S, Arii S. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol 2010; 15: 235-241
46. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
47. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
48. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240
49. Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs 2010; 19: 663-672
50. Rimassa L, Santoro A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S273-S280
51. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010; 79: 85-92